Navigation Links
Kendle Rated a Top CRO to Work with for Fourth Consecutive Year
Date:6/3/2010

CINCINNATI, June 3 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization (CRO), today announced it is ranked a top CRO to work with in the 2010 CenterWatch European Investigative Site Survey. Kendle is the only CRO to be ranked consistently among the top three providers for each of the past four years in the annual U.S. and European site surveys conducted by CenterWatch, a leading publishing and information services company focusing on the clinical trials industry. In the 2010 survey of investigative sites across 30 European countries Kendle was rated a top-three CRO on 21 of the 29 individual survey attributes and in particular ranked highly in the study initiation category, receiving the highest percentage of "excellent" ratings for its protocol design (48.5 percent) and for protocols aligning scientific rationale with clinical practice realities (50 percent).

"Kendle's ability to forge strong and collaborative relationships with investigative sites across the globe is key to our ability to deliver studies more efficiently and cost effectively for our customers, which is increasingly important in today's environment," said Stephen Cutler, PhD, Senior Vice President and Chief Operating Officer. "Our continued recognition as a top-rated CRO and the fact that we are the only CRO to have been ranked consistently among the top three providers since 2007 is a further testament to our ability to build long-lasting and successful site relationships in support of our customers' needs."

In the 2010 European Investigative Site Survey, 76.1 percent of sites rated Kendle "Good" or "Excellent" for overall relationship quality. In addition to excelling in the study initiation category Kendle also scored highly on the ongoing study conduct and grant payment performance attributes. In an article detailing the survey results in the June 2010 issue of The CenterWatch Monthly, CenterWatch notes "Kendle has stayed true to their word of continuous improvement from previous years— actively listening to the needs of investigative sites, implementing change when needed—and generally adopting a proactive strategy to strengthen their relationships with sites."

CenterWatch conducted the survey of investigative sites across Europe between January and March 2010. The biennial survey, which has been conducted since 1997 in both North America and Europe, was developed with input from clinical research professionals at sponsor companies, CROs and investigative sites. A total of 924 investigative sites completed the survey, which evaluated the performance of CROs across 29 specific relationship attributes relating to general project management, personnel and work-style and project-specific areas. In addition, sites also provided feedback on the importance of these attributes when conducting their clinical trials.

Kendle's rating as a top CRO in the 2010 European Investigative Site Survey follows its strong performance in the annual CenterWatch investigative site surveys during each of the past four years. In the 2009 CenterWatch survey of U.S. investigative sites Kendle ranked second with 72 percent of sites surveyed rating the Company as "Good" or "Excellent." Kendle also ranked second in the 2008 CenterWatch Survey of European Investigative Sites and ranked first overall in the 2007 CenterWatch Survey of U.S. Investigative Sites.

About Kendle

Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing drugs to market for the benefit of patients worldwide. As one of the world's largest global providers of Phase I-IV services, we offer experience spanning more than 100 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges.

Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 500, Cincinnati, OH 45202 or from the Company's Web site at www.kendle.com.


'/>"/>
SOURCE Kendle International Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Kendle Announces New Revolving Credit Facility
2. Kendle Announces Details Regarding Fourth Quarter and Full-Year 2009 Earnings Conference Call and Webcast
3. Kendle to Present at UBS Global Life Sciences Conference
4. Kendle to Present at Robert Baird 2009 Health Care Conference
5. Kendle Realigns C-Suite Leadership to Drive Increased Innovation, Productivity and Organizational Efficiency
6. Kendle Appoints Stephen Cutler, PhD Senior Vice President and Chief Operating Officer
7. Kendle Names Jarrod Pontius Chief Legal Officer
8. Kendle Expands Asia/Pacific Operations with Opening of Offices in Kuala Lumpur, Bangkok and Manila
9. Kendle Announces First Quarter 2009 Results
10. Kendle Announces Departure of Senior Vice President and CFO Karl Buzz Brenkert III; Appoints Keith A. Cheesman as Successor
11. Kendle to Host Conference Call to Discuss Revised 2009 Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Newly created ... services and solutions to the healthcare market. The company's primary focus is on ... sales and marketing strategies that are necessary to help companies efficiently bring their ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) is ... treatments and faster cures for prostate cancer. Members of the Class of 2016 ... countries. Read More About the Class of 2016 PCF ... ... ...
Breaking Biology Technology:
(Date:5/24/2016)... , May 24, 2016 Ampronix facilitates superior patient care by providing unparalleled ... medical LCD display is the latest premium product recently added to the range of ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC , ... announced the opening of an IoT Center of Excellence ... and expand the development of embedded iris biometric applications. ... level of convenience and security with unmatched biometric accuracy, ... identity aside from DNA. EyeLock,s platform uses video technology ...
(Date:5/9/2016)... May 9, 2016 Elevay is ... to expanding freedom for high net worth professionals seeking ... today,s globally connected world, there is still no substitute ... ever duplicate sealing your deal with a firm handshake. ... by taking advantage of citizenship via investment programs like ...
Breaking Biology News(10 mins):